Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E.

Mol Chem Neuropathol. 1995 Dec;26(3):231-45.

PMID:
8748926
2.

[Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].

Hu Y, He S, Wang J.

Zhonghua Yi Xue Za Zhi. 2001 Nov 25;81(22):1377-9. Chinese.

PMID:
11930632
3.

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K.

Arch Gen Psychiatry. 2004 Jan;61(1):95-102.

PMID:
14706948
4.
5.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
6.

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.

JAMA. 2003 Apr 23-30;289(16):2094-103. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
12709467
7.

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H.

Arch Neurol. 2002 Aug;59(8):1267-72.

PMID:
12164722
8.

Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?

Mecocci P, Cherubini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal DT, Senin U.

Alzheimer Dis Assoc Disord. 1998 Sep;12(3):211-4.

PMID:
9772026
9.

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C, Blennow K.

Neurodegeneration. 1995 Dec;4(4):433-42.

PMID:
8846237
10.

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis.

Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, Urbani A, Giordano A, Martorana A, Orlacchio A, Federici G, Bernardi G.

J Neurol Sci. 2005 Oct 15;237(1-2):83-8.

PMID:
15990115
11.

Analysis of combined CSF biomarkers in AD diagnosis.

De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, Bolner A, Perini F.

Clin Lab. 2014;60(4):629-34.

PMID:
24779297
12.

Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.

Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, Holtzman DM.

Alzheimer Dis Assoc Disord. 2012 Oct-Dec;26(4):314-21. doi: 10.1097/WAD.0b013e31823c0cf4.

PMID:
22156755
13.

Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.

Leszek J, Małyszczak K, Janicka B, Kiejna A, Wiak A.

Med Sci Monit. 2003 Nov;9(11):CR484-8.

PMID:
14586274
14.

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, Kohno H, Imahori K.

Neurosci Lett. 1999 Jul 30;270(2):91-4.

PMID:
10462105
15.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
16.

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Neurology. 1999 Oct 22;53(7):1488-94.

PMID:
10534256
17.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
18.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.

Acta Neurol Scand Suppl. 2003;179:47-51.

PMID:
12603251
19.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
20.

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.

Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM.

Neurology. 2012 Jan 3;78(1):47-54. doi: 10.1212/WNL.0b013e31823ed0f0. Epub 2011 Dec 14.

PMID:
22170879

Supplemental Content

Support Center